Abstracts Archive - Page 1327 of 2425 - ACR Meeting Abstracts

Abstract Number: 1822 • 2017 ACR/ARHP Annual Meeting
The Effect of Sarilumab in Combination with Dmards on Fasting Glucose and Glycosylated Hemoglobin in Patients with Rheumatoid Arthritis with and without Diabetes
Mark C. Genovese¹, Roy Fleischmann², Owen Hagino³, Chih-Chi Hu⁴, Claudia Pena-Rossi³, Jonathan Sadeh³, Neil M.H. Graham⁵, Erin K. Mangan⁵, Hubert van Hoogstraten⁴ and Thomas Mandrup-Poulsen⁶, ¹Stanford University Medical Center, Palo Alto, CA, ²Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, ³Sanofi, Bridgewater, NJ, ⁴Sanofi Genzyme, Bridgewater, NJ, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶University of Copenhagen, Copenhagen, Denmark
Background/Purpose: IL-6 involvement has been reported in glucose metabolism.1-4 Sarilumab, a human mAb blocking the IL-6Rɑ, was evaluated for treatment of RA in 3 clinical…
Abstract Number: 1823 • 2017 ACR/ARHP Annual Meeting
Methotrexate Requires High Serum BAFF Levels to Prevent Immunization Against TNF-α Inhibitors
Samuel Bitoun¹, Pierre Dönnes², Aline Doublet³, Kimberly Florence⁴, Agnes Hincelin-Mery⁵, Gaetane Nocturne⁶, Mattieu Allez⁷, N Ruperto⁸, Marc Pallardy⁹ and Xavier Mariette¹⁰, ¹INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicëtre, France, ²SciCross AB, Skövde, Sweden, ³Department of Rheumatology, Kremlin-Bicêtre hospital INSERM U1184, Le Kremlin Bicêtre, France, ⁴Immunogenicity and Clinical Immunology, GlaxoSmithKline, King of Prussia, PA, ⁵Sanofi, Chilly-Mazarin, France, ⁶INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicêtre, France, ⁷Department of Gastroenterology, Hopital Saint-Louis, APHP, Paris, France, ⁸PRINTO Coordinating Centre, Genoa, Italy, ⁹Inflammation, Chimiokines et Immunopathologie, INSERM UMR 996, Faculté de Pharmacie, Chatenay Mallabry, France, ¹⁰Université Paris Sud, Paris, France
Background/Purpose: Immunization against TNF Inhibitors (TNFi) is observed in 30-50% of patients with inflammatory rheumatic diseases. With most TNFi, anti-drug antibodies (ADA) lead to rapid…
Abstract Number: 1824 • 2017 ACR/ARHP Annual Meeting
Evaluation of Pneumococcal and Tetanus Vaccine Responses in Patients with Rheumatoid Arthritis Receiving Baricitinib: Results from a Long-Term Extension Trial Substudy
Kevin Winthrop¹, Clifton O. Bingham III², John D. Bradley³, Maher Issa³, Rena Klar⁴ and Cynthia E. Kartman³, ¹Oregon Health and Sciences University, Portland, OR, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Eli Lilly and Company, Indianapolis, IN, ⁴Quintiles IMS Holdings, Inc., Durham, NC
Background/Purpose: Clinical guidelines recommend pneumococcal and tetanus vaccinations in patients (pts) with RA.1 Baricitinib (bari) is an oral, selective Janus kinase (JAK) 1/JAK 2 inhibitor…
Abstract Number: 1825 • 2017 ACR/ARHP Annual Meeting
Comparative Analysis of Achievement of Individual Important Response Measured By DAS28dcrit in a Randomized Head-to-Head Trial of Tocilizumab Vs. Adalimumab in Active Rheumatoid Arthritis
Michaela Koehm¹, Michael Hofmann², Rasmus Lüthje², Matthew McIntosh³, Varghese Abraham³, Cem Gabay⁴, Arthur Kavanaugh⁵, Harald Burkhardt⁶ and Frank Behrens⁶, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ²Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, ³Genentech, San Francisco, CA, ⁴SCQM, Geneva, Switzerland, Geneva, Switzerland, ⁵Medicine, University of California, San Diego, La Jolla, CA, ⁶Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany
Background/Purpose: Fluctuations in disease activity due to short-term situational effects and measurement errors are important considerations for evaluation of individual clinically meaningful therapeutic response in…
Abstract Number: 1826 • 2017 ACR/ARHP Annual Meeting
Secukinumab Achievement of Psoriatic Arthritis Disease Activity Score (PASDAS) Related Remission: 2-Year Results from a Phase 3 Study
Laura C Coates¹, Dafna D Gladman², Peter Nash³, Oliver FitzGerald⁴, Arthur Kavanaugh⁵, Lawrence Rasouliyan⁶, Luminita Pricop⁷, Kevin Ding⁷ and Corine Gaillez⁸, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Toronto Western Hospital, Toronto, ON, Canada, ³University of Queensland, Brisbane, Australia, ⁴St Vincent's University Hospital, Dublin, Ireland, ⁵UC San Diego School of Medicine, La Jolla, CA, ⁶RTI Health Solutions, Barcelona, Spain, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Psoriatic arthritis (PsA) disease activity score (PASDAS) assessing multiple facets of PsA was demonstrated to distinguish treatment effect, perform better in statistical terms than…
Abstract Number: 1827 • 2017 ACR/ARHP Annual Meeting
Comparison of Ixekizumab and Ustekinumab Efficacy in the Treatment of Nail Lesions of Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Data from a Phase 3 Trial
Pierre-Dominique Ghislain¹, Curdin Conrad², Yves Dutronc³, Carsten Henneges³, David Sandoval Calderon³, Myriam Vincent³, Liesbet Ghys³, Jolien de Gruijter³ and Peter C M van de Kerkhof⁴, ¹Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ³Eli Lilly and Company, Indianapolis, IN, ⁴Department of Dermatology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Background/Purpose: Nails are frequently involved in psoriasis and represent one of the most difficult to treat manifestations of the disease. This study evaluated the comparative…
Abstract Number: 1828 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Study
Karel Pavelka¹, Alan J. Kivitz², Eva Dokoupilova³, Ricardo Blanco⁴, Marco Maradiaga⁵, Hasan Tahir⁶, Alan Slade⁷, Yi Wang⁷, Susanne Rohrer⁸ and Brian Porter⁷, ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Altoona Center for Clinical Research, Duncansville, PA, ³MEDICAL PLUS s.r.o., Uherske Hradiste, Czech Republic, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, Mexico, ⁶Barts Health NHS Trust, London, United Kingdom, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) improved the signs and symptoms of AS in 2 Phase 3 studies (MEASURE 1 and 2).1,2 Here, we present interim results through…
Abstract Number: 1829 • 2017 ACR/ARHP Annual Meeting
Patterns and Predictors of Progression of Sacroiliitis in Psoriatic Arthritis and Its Relationship with Human Leukocyte Antigen (HLA) Alleles. Results from the Toronto Cohort
Musaab Elmamoun¹, Justine (Yang) Ye², Richard J. Cook³, Vinod Chandran⁴ and Dafna D Gladman⁵, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁴Medicine, Krembil Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is clinically heterogeneous, with broad phenotypes of musculoskeletal (MSK) involvement including peripheral arthritis, enthesitis, dactylitis, and axial involvement. Sacroiliitis (SI) in…
Abstract Number: 1830 • 2017 ACR/ARHP Annual Meeting
Bone Marrow Edema in Sacroiliac Joints of Young Athletes Is Common and Shows Most Frequently in the Posterior Lower Ilium
Ulrich Weber¹, Anne Grethe Jurik², Anna Zejden³, Ejnar Larsen⁴, Steen Hylgaard Jørgensen⁵, Kaspar Rufibach⁶, Christian Schioldan⁷ and Søren Schmidt-Olsen⁵, ¹Department of Research, King Christian 10th Hospital for Rheumatic Diseases, Graasten, Denmark, ²Dept. of Radiology, Aarhus University Hospital, Aarhus, Denmark, ³Radiology, Aarhus University Hospital, Aarhus, Denmark, ⁴Radiology, North Denmark Regional Hospital, Hjørring, Denmark, ⁵Rheumatology and Sports Medicine, North Denmark Regional Hospital, Hjørring, Denmark, ⁶Biostatistics, F. Hoffmann-La Roche, Basel, Switzerland, Basel, Switzerland, ⁷Physiotherapy, Clinic Benefit, Frederikshavn, Denmark
Background/Purpose: Low grade bone marrow edema (BME) was reported in the sacroiliac joints (SIJ) of up to 25% of healthy individuals and mechanical back pain…
Abstract Number: 1831 • 2017 ACR/ARHP Annual Meeting
A Positive MRI of the Sacroiliac Joints Is Not Specific for Axial Spondyloarthritis but Frequently Occurs in Healthy Individuals
Janneke de Winter¹, Manouk de Hooge², Marleen van de Sande¹, Lonneke van Hoeven³, Jet de Jong¹, Anoek de Koning², Inger Jorid Berg⁴, Roberta Ramonda⁵, Dominique Baeten^1,6, Désirée van der Heijde⁷, Angelique Weel⁸ and Robert B.M. Landewé⁹, ¹Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy, ⁶UCB Pharma, Slough, United Kingdom, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁹Amsterdam Rheumatology & Immunology Center, Academic Medical Center, Amsterdam, Netherlands
Background/Purpose: Inflammation shown on MRI of the sacroiliac joint (MRI-SI) is prevalent in axSpA (±30%) but the specificity is not well known, hence we compared…
Abstract Number: 1832 • 2017 ACR/ARHP Annual Meeting
Gut Dysbiosis Contributes to Autoimmune Pathogenesis in Lupus-Prone Mice
Seung Chul Choi¹, Josephine Brown¹, Mansour Mohamadzadeh², Byron Croker¹ and Laurence Morel³, ¹Pathology, University of Florida, Gainesville, FL, ²Infectious Diseases & Pathology, University of Florida, Gainesville, FL, ³Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL
Background/Purpose: Multiple studies have demonstrated that commensal bacteria play an immunoregulatory role and that gut dysbiosis is associated with inflammatory diseases. This study was conducted…
Abstract Number: 1833 • 2017 ACR/ARHP Annual Meeting
iRhom2 Deficiency Protects Fcgr2b-/- Lupus-Prone Mice from Kidney Damage By Modulating ADAM17-Dependent Shedding of TNF-α and EGFR Ligand
Xiaoping Qing¹, Yurii Chinenov², Patricia M. Redecha³, Michael Madaio⁴, Priya Issuree⁵, David McIlwain⁶, Tak Mak⁷, Carl Blobel⁵ and Jane E. Salmon⁸, ¹Program in Inflammation and Autoimmunity, Hospital for Special Surgery, New York, NY, ²Arthritis & Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, ³Autoimmunity & Inflammation, Hospital for Special Surgery, New York, NY, ⁴Medicine, Medical College of Georgia, Augusta, GA, ⁵Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, ⁶Department of Microbiology and Immunology, Stanford University, Stanford, CA, ⁷Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Center, Toronto, ON, Canada, ⁸Medicine/Rheumatology, Hospital of Special Surgery, New York, NY
Background/Purpose: A disintegrin and metalloprotease 17 (ADAM17) controls ecto-domain shedding of TNFα and epithelial-growth factor ligands (EGFR) such as heparin-binding EGF (HB-EGF). TNFa and HB-EGF…
Abstract Number: 1834 • 2017 ACR/ARHP Annual Meeting
Selective Inhibitors of Nuclear Export Prevent Lupus Progression By Targeting Germinal Center Formation and Autoreactive Antibody Secreting Cells
Javier Rangel-Moreno¹, Jennifer Barnard², Shelton Cochran³, Margaret Lee³, Sharon Tamir³ and Jennifer H. Anolik⁴, ¹Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Medicine-Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Karyopharm Therapeutics, Newton, MA, ⁴Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: There is great interest in developing new treatment approaches for systemic lupus erythematosus (SLE), but the biologic therapies under investigation over the past several…
Abstract Number: 1835 • 2017 ACR/ARHP Annual Meeting
Microglial Defects Contribute to Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
Hadijat Makinde¹, Philip J. Homan², Harris Perlman² and Carla Cuda², ¹Northwestern University, Chicago, IL, ²Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Neuropsychiatric symptoms of systemic lupus erythematosus (NP-SLE), including headaches, cognitive dysfunction and psychiatric disorders, appear in up to 75% of SLE patients and may…
Abstract Number: 1836 • 2017 ACR/ARHP Annual Meeting
Amelioration of Neuropsychiatric Systemic Lupus Erythematosus By Fingolimod-Mediated Sphingosine-1-Phosphate Receptor Modulation
Elise Mike¹, Ariel Stock¹ and Chaim Putterman², ¹Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ²Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: While the pathogenesis of neuropsychiatric SLE (NPSLE) is not fully understood, critical aspects of disease development include neuroinflammation and loss of brain barrier integrity.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].